Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • ENO1, Lactate, and Apoptosis After MI

    2026-11-03

    How does macrophage metabolism influence the transition from inflammatory injury to cardiac repair after myocardial infarction? Li et al. addressed this question by examining whether enolase 1 (ENO1), a glycolytic enzyme, helped sustain inflammatory macrophage behavior and whether interrupting that metabolic state could improve postinfarction remodeling. Their central model connected four levels of biology: increased ENO1 expression, enhanced glycolytic activity and lactate accumulation, suppression of the reparative transcription factor KLF4, and persistence of inflammatory signaling. The study then tested whether targeted ENO1 silencing could alter both macrophage state and cardiac outcomes. source A

    Why ENO1 became the study’s candidate checkpoint

    The discovery phase combined transcriptomic and network-based evidence rather than beginning with a single candidate selected only from prior literature. Bulk RNA sequencing of murine postinfarction macrophages showed increased glycolytic activity during the early inflammatory phase. The investigators intersected differentially expressed genes with glycolysis-related enzymes and identified 14 overlapping candidates. Protein–protein interaction analysis and degree-based hub ranking placed ENO1 among the leading metabolic nodes. source A

    Human relevance was examined through a single-cell transcriptomic dataset from myocardial infarction tissue. Within CSF1R-positive and CD68-positive macrophage populations, ENO1, ENO2, LDHA, and PKM were reported as increased in acute infarction tissue, with ENO1 showing prominent statistical support. The human macrophage comparison was reported as statistically significant at P = 0.00485. This cross-species concordance strengthened the case that ENO1 was not simply an artifact of one murine model, although expression concordance alone did not establish that ENO1 caused inflammatory dysfunction. source A

    What mechanism did the study propose?

    The proposed mechanism was metabolic rather than a direct transcription-factor interaction. In inflammatory macrophage cultures, Eno1 expression and ENO1 protein increased alongside inflammatory stimulation. Pharmacological ENO1 inhibition reduced the expression of inflammatory markers including Il-1β, Tnf-α, and Nos2. These experiments used three biological replicates, and the reported comparisons reached significance ranging from P < 0.05 to P < 0.0001, depending on the marker and comparison. source A

    The authors interpreted these findings through an ENO1–lactate–KLF4 axis. ENO1 silencing was reported to reduce glycolytic flux and lactate accumulation. Lower lactate was then associated with recovery of KLF4, a transcription factor linked to reparative macrophage programs and cooperation with STAT6. Importantly, the reported co-immunoprecipitation and rescue experiments argued against a direct ENO1–KLF4 protein interaction. Instead, ENO1 was proposed to influence KLF4 indirectly through a metabolic intermediate. That distinction matters: the study supports metabolic–transcriptional cross-talk, not direct binding between the enzyme and transcription factor. source A

    How the evidence layers fit together

    Evidence layer Reported observation What it supports
    Murine transcriptomics Glycolytic activity and ENO1-associated signatures increased after infarction. ENO1 was a plausible candidate linked to the inflammatory metabolic state.
    Human single-cell data ENO1 expression was higher in macrophages from infarcted hearts than in donor hearts. The candidate had clinical-context relevance across species.
    Cellular perturbation ENO1 inhibition or silencing reduced inflammatory markers and altered lactate–KLF4 relationships. ENO1 participated in macrophage-state regulation, although inhibitor specificity and model simplicity remain considerations.
    In vivo intervention Responsive delivery of siENO1 was associated with reduced tissue injury and improved ventricular function. The proposed pathway had preclinical therapeutic relevance in the tested model.
    Apoptosis-associated measurement Cardiomyocyte apoptosis was assessed as one downstream injury outcome. The intervention’s tissue-level consequences could be related to cell death, but the readout did not by itself identify the upstream cause.

    This structure was a strength of the work because no single assay carried the entire argument. Transcriptomics supported candidate selection, cellular perturbation addressed mechanism, and animal outcomes tested physiological relevance. At the same time, the layers were not interchangeable. A change in ENO1 expression is not equivalent to proof of altered enzymatic flux; a reduction in inflammatory transcripts is not equivalent to durable reparative function; and reduced apoptosis-associated signal is not equivalent to proof that ENO1 silencing directly rescued cardiomyocytes.

    What did the nanotherapeutic intervention add?

    The delivery system was designed around a feature of the infarct microenvironment: acidity. The authors described an acid-responsive carrier that exposed phosphatidylserine-like recognition signals in the infarct region, thereby favoring uptake by phagocytic macrophages. This design was intended to improve cellular selectivity for siENO1 delivery while using the macrophage’s physiological recognition machinery. The study therefore tested not only whether ENO1 was biologically relevant, but also whether a microenvironment-responsive delivery concept could connect that target to the cell population of interest. source A

    In vivo, siENO1 delivered through the responsive carrier was reported to reduce infarct size, fibrosis, and cardiomyocyte apoptosis while improving ventricular function. These were directionally coherent with the proposed shift away from persistent inflammatory metabolism. However, the reported summary establishes the direction of these outcomes without supplying numerical effect sizes for each endpoint. The results should therefore be read as evidence of preclinical efficacy in the tested model, not as a quantitative estimate of clinical benefit. source A

    Where Annexin V fits in the interpretation

    The study-associated Annexin V-PE Apoptosis Kit, listed as catalog K2281, occupied a measurement role within the apoptosis analysis rather than an intervention role. Annexin V binds cell-surface phosphatidylserine, a membrane-state change commonly associated with apoptosis. This makes it useful for flow cytometry apoptosis detection and fluorescence microscopy apoptosis detection, particularly when the research question concerns cell surface phosphatidylserine exposure as an early apoptosis marker.

    That measurement principle also sets an interpretive boundary. Phosphatidylserine exposure is apoptosis-associated but not uniquely diagnostic of one causal pathway. Its meaning depends on cell identity, disease stage, membrane integrity, and the other measurements used alongside it. In the ENO1 study, Annexin V signal could support the claim that the intervention was associated with fewer apoptosis-related membrane changes in cardiac tissue. It could not, by itself, establish that ENO1 silencing caused the change, that lactate was the exclusive mediator, or that macrophage reprogramming was the sole route to cardiomyocyte preservation. The apoptosis assay was therefore a downstream outcome measure within a larger causal argument.

    What comparisons are scientifically meaningful?

    The most informative comparison in this work was between evidence types, not between fluorescent labels or assay formats. ENO1 expression data addressed association; pharmacological and genetic perturbations addressed functional involvement; lactate and KLF4 measurements addressed the proposed intermediary mechanism; and infarct remodeling, ventricular function, and apoptosis addressed tissue-level consequences. Concordance across these levels made the checkpoint model more persuasive than any individual result.

    Nevertheless, the study did not make every causal separation equally strong. Pharmacological inhibition can affect proteins or pathways beyond the intended target, whereas siRNA delivery can vary in cellular distribution and intracellular activity. The responsive carrier was designed to favor macrophage uptake, but preferential uptake does not prove exclusive delivery to macrophages or exclude effects in other infarct-associated cells. Similarly, reduced cardiomyocyte apoptosis may reflect altered inflammatory cytokines, extracellular matrix remodeling, perfusion, or other secondary changes rather than a direct macrophage-to-cardiomyocyte mechanism. source A

    Limitations and transferability

    The macrophage compartment is heterogeneous. The study distinguished inflammatory populations using markers such as IL-1β and CXCL10 and reparative populations using SPP1 and TREM2, but marker-defined states are not identical to stable cell types. Macrophage identities also vary with tissue location, disease stage, and species. The human single-cell analysis provided relevance, yet it was observational and could not reproduce the causal perturbations performed in experimental models.

    The proposed lactate–KLF4 connection was supported by biochemical and rescue logic, but the broader inflammatory phenotype is likely to involve additional metabolic products, signaling pathways, and cell–cell interactions. The abstract reported improved ventricular function and reduced remodeling, but the material provided here does not give the magnitude, uncertainty intervals, or full duration of those benefits. Nor does it establish whether the intervention’s effects persist, whether they depend on a particular therapeutic window, or how the delivery system would behave in the diverse inflammatory environments of human infarction.

    Overall assessment

    Li et al. presented a coherent preclinical framework in which ENO1 linked macrophage glycolysis to lactate accumulation, KLF4 suppression, inflammatory polarization, and adverse cardiac remodeling. The strength of the study was its convergence of transcriptomic discovery, cellular perturbation, mechanistic rescue, responsive delivery, and organ-level outcomes. Annexin V fluorescence added a focused apoptosis-associated readout, but it remained downstream evidence rather than proof of mechanism. Finally, the identity and intended assay role of a cataloged Annexin V reagent do not establish therapeutic efficacy; those claims depend on the study’s full experimental evidence, controls, quantitative outcomes, and independent replication.

    Publication: Targeting the ENO1 metabolic checkpoint via microenvironment-responsive nanotherapeutics promotes postinfarction cardiac repair.